A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 145 in Subjects With Hyperlipidemia on Stable Doses of a Statin.

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 145 in Subjects With Hyperlipidemia on Stable Doses of a Statin.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 15 Nov 2016 Results of pooled analysis from this and other study (20080397 and 20080398) assessing pharmacokinetic-pharmacodynamic relationship of evolocumab published in the Journal of Clinical Pharmacology.
    • 21 Oct 2015 HMG-CoA-reductase-inhibitors removed from treatment as reported by ClinicalTrials.gov.
    • 27 Mar 2012 Results presented at the 61st Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top